🚀 VC round data is live in beta, check it out!
Alcon Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alcon and similar public comparables like Agilent, GE HealthCare, Edwards Lifesciences, IDEXX Laboratories and more.
Alcon Overview
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Founded
1945
HQ
Employees
25.9K
Website
Financials (LTM)
EV
$44B
Alcon Financials
Alcon reported last 12-month revenue of $11B and EBITDA of $3B.
In the same LTM period, Alcon generated $6B in gross profit, $3B in EBITDA, and $2B in net income.
Revenue (LTM)
Alcon P&L
In the most recent fiscal year, Alcon reported revenue of $10B and EBITDA of $3B.
Alcon expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11B | XXX | $10B | XXX | XXX | XXX |
| Gross Profit | $6B | XXX | $6B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $3B | XXX | $3B | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alcon Stock Performance
Alcon has current market cap of $40B, and enterprise value of $44B.
Market Cap Evolution
Alcon's stock price is $81.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44B | $40B | -0.2% | XXX | XXX | XXX | $3.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlcon Valuation Multiples
Alcon trades at 4.1x EV/Revenue multiple, and 16.1x EV/EBITDA.
EV / Revenue (LTM)
Alcon Financial Valuation Multiples
As of April 20, 2026, Alcon has market cap of $40B and EV of $44B.
Equity research analysts estimate Alcon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alcon has a P/E ratio of 25.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40B | XXX | $40B | XXX | XXX | XXX |
| EV (current) | $44B | XXX | $44B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 16.1x | XXX | 16.2x | XXX | XXX | XXX |
| EV/EBIT | 20.5x | XXX | 21.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | 7.6x | XXX | XXX | XXX |
| P/E | 25.2x | XXX | 26.1x | XXX | XXX | XXX |
| EV/FCF | 27.1x | XXX | 27.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alcon Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alcon Margins & Growth Rates
Alcon's revenue in the last 12 month grew by 8%.
Alcon's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Alcon's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alcon's rule of X is 45% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alcon Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alcon Public Comps
See public comps and valuation multiples for other Medical Devices and Hospitals & Clinics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alcon | XXX | XXX | XXX | XXX | XXX | XXX |
| Agilent | XXX | XXX | XXX | XXX | XXX | XXX |
| GE HealthCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Edwards Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| IDEXX Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| ResMed | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alcon M&A Activity
Alcon acquired XXX companies to date.
Last acquisition by Alcon was on XXXXXXXX, XXXXX. Alcon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alcon
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlcon Investment Activity
Alcon invested in XXX companies to date.
Alcon made its latest investment on XXXXXXXX, XXXXX. Alcon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alcon
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alcon
| When was Alcon founded? | Alcon was founded in 1945. |
| Where is Alcon headquartered? | Alcon is headquartered in Switzerland. |
| How many employees does Alcon have? | As of today, Alcon has over 25K employees. |
| Who is the CEO of Alcon? | Alcon's CEO is David J. Endicott. |
| Is Alcon publicly listed? | Yes, Alcon is a public company listed on NYSE. |
| What is the stock symbol of Alcon? | Alcon trades under ALC ticker. |
| When did Alcon go public? | Alcon went public in 2019. |
| Who are competitors of Alcon? | Alcon main competitors are Agilent, GE HealthCare, Edwards Lifesciences, IDEXX Laboratories. |
| What is the current market cap of Alcon? | Alcon's current market cap is $40B. |
| What is the current revenue of Alcon? | Alcon's last 12 months revenue is $11B. |
| What is the current revenue growth of Alcon? | Alcon revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Alcon? | Current revenue multiple of Alcon is 4.1x. |
| Is Alcon profitable? | Yes, Alcon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alcon? | Alcon's last 12 months EBITDA is $3B. |
| What is Alcon's EBITDA margin? | Alcon's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Alcon? | Current EBITDA multiple of Alcon is 16.1x. |
| What is the current FCF of Alcon? | Alcon's last 12 months FCF is $2B. |
| What is Alcon's FCF margin? | Alcon's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Alcon? | Current FCF multiple of Alcon is 27.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.